223 related articles for article (PubMed ID: 11515348)
1. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.
Doan TT; Wang Q; Griffin JS; Lukasik NL; O'Dea RF; Pan WJ
Am J Health Syst Pharm; 2001 Aug; 58(16):1512-9. PubMed ID: 11515348
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules.
Amer F; Karol MD; Pan WJ; Griffin JS; Lukasik NL; Locke CS; Chiu YL
Clin Ther; 2004 Dec; 26(12):2076-83. PubMed ID: 15823771
[TBL] [Abstract][Full Text] [Related]
3. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation.
Chun AH; Erdman K; Chiu YL; Pilmer BL; Achari R; Cavanaugh JH
Clin Ther; 2002 Aug; 24(8):1322-31. PubMed ID: 12240782
[TBL] [Abstract][Full Text] [Related]
5. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate.
Sharma VK; Peyton B; Spears T; Raufman JP; Howden CW
Aliment Pharmacol Ther; 2000 Jul; 14(7):887-92. PubMed ID: 10886044
[TBL] [Abstract][Full Text] [Related]
6. Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods.
Chun AH; Erdman K; Zhang Y; Achari R; Cavanaugh JH
Clin Ther; 2000 Feb; 22(2):231-6. PubMed ID: 10743982
[TBL] [Abstract][Full Text] [Related]
7. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube.
Chun AH; Shi HH; Achari R; Dennis S; Cavanaugh JH
Clin Ther; 1996; 18(5):833-42. PubMed ID: 8930427
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects.
Freston JW; Chiu YL; Mulford DJ; Ballard ED
Aliment Pharmacol Ther; 2003 Feb; 17(3):361-7. PubMed ID: 12562448
[TBL] [Abstract][Full Text] [Related]
9. The effects of oral doses of lansoprazole and omeprazole on gastric pH.
Tolman KG; Sanders SW; Buchi KN; Karol MD; Jennings DE; Ringham GL
J Clin Gastroenterol; 1997 Mar; 24(2):65-70. PubMed ID: 9077718
[TBL] [Abstract][Full Text] [Related]
10. Lansoprazole: an alternative method of administration of a capsule dosage formulation.
Chun AH; Eason CJ; Shi HH; Cavanaugh JH
Clin Ther; 1995; 17(3):441-7. PubMed ID: 7585848
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole.
Sharma VK
Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S18-21. PubMed ID: 10597120
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease.
Gremse D; Winter H; Tolia V; Gunasekaran T; Pan WJ; Karol M; Chiu YL; Pilmer B; Book L
J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S319-26. PubMed ID: 12607792
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.
Tran A; Rey E; Pons G; Pariente-Khayat A; D'Athis P; Sallerin V; Dupont C
Clin Pharmacol Ther; 2002 May; 71(5):359-67. PubMed ID: 12011821
[TBL] [Abstract][Full Text] [Related]
14. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers.
Bell NJ; Hunt RH
Aliment Pharmacol Ther; 1996 Dec; 10(6):897-904. PubMed ID: 8971286
[TBL] [Abstract][Full Text] [Related]
15. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants.
Undre N; Dickinson J
BMJ Open; 2017 Apr; 7(4):e012252. PubMed ID: 28377389
[TBL] [Abstract][Full Text] [Related]
16. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion.
Blum RA; Shi H; Karol MD; Greski-Rose PA; Hunt RH
Clin Ther; 1997; 19(5):1013-23. PubMed ID: 9385488
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole.
Freston JW; Pilmer BL; Chiu YL; Wang Q; Stolle JC; Griffin JS; Lee CQ
Aliment Pharmacol Ther; 2004 May; 19(10):1111-22. PubMed ID: 15142201
[TBL] [Abstract][Full Text] [Related]
18. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
19. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients.
Thomson AB; Kirdeikis P; Lastiwka R; Röhss K; Sinclair P; Olofsson B
Can J Gastroenterol; 1997; 11(8):657-60. PubMed ID: 9459044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
